Mumbai, January 29, 2025 – Solara Active Pharma Sciences Limited (NSE: SOLARA, BSE: 541540) has announced its unaudited financial results for Q3 FY25, reporting robust revenue growth and a return to profitability.
Key Financial Highlights (Q3 FY25 - Consolidated)
- Revenue from Operations: ₹301.80 crores (vs. ₹273.18 crores in Q3 FY24), marking a 10.5% YoY increase.
- Total Income: ₹308.21 crores.
- Profit Before Tax (PBT): ₹8.10 crores (vs. a loss of ₹(27.36) crores in Q3 FY24), demonstrating a strong turnaround.
- Net Profit (PAT): ₹8.07 crores (vs. a loss of ₹(27.54) crores in Q3 FY24).
- Earnings Per Share (EPS): ₹2.63 (vs. ₹(7.21) in Q3 FY24).
Nine-Month Financial Overview (9MFY25 - Consolidated)
- Total Revenue: ₹1,013.14 crores (vs. ₹975.92 crores in 9MFY24), a 3.8% YoY growth.
- Net Profit: ₹3.10 crores (vs. a loss of ₹(148.27) crores in 9MFY24), highlighting profitability restoration.
- Total Comprehensive Income: ₹3.12 crores, showing improved financial stability.
Expense Analysis & Cost Control
- Material Costs: ₹149.63 crores, reflecting efficient procurement strategies.
- Employee Benefits Expense: ₹31.87 crores.
- Finance Costs: ₹25.40 crores.
- Depreciation & Amortization: ₹25.45 crores.
- Other Expenses: ₹56.09 crores.
Corporate Developments & Financial Strategy
- Rights Issue Utilization: ₹157.48 crores raised via rights issue on June 19, 2024, with funds allocated to repayment of outstanding borrowings (₹118.61 crores) and general corporate purposes (₹35.87 crores).
- Debt Position: Total financial indebtedness stands at ₹806.11 crores, with no outstanding defaults.
- Future Expansion: The company is exploring a demerger of its CRAMS and Polymers business into a separate listed entity.